Targeting hypoxia-inducible factor-1 for therapy and prevention

Bibliography

• SEMENZA GL, WANG GL: A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. MM. Cell Biol. (1992) 12:5447–5454.
   Web of Science ®Google Scholar
• ••Primary discovery of HIF-la and HRE.
   Google Scholar
• WANG GL, JIANG BH, RUE EA, SEMENZA GL: Hypwda-inducible factor-1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular 02 tension. Proc. Nati Acad. Sci. USA (1995) 92:5510–5514.
   PubMed Web of Science ®Google Scholar
• •Identification of H1F-1a as a member of the bHLH-PAS family.
   Google Scholar
• SEMENZA GL: Targeting HIF-1 for cancer therapy. Nat. Rev Cancer (2003) 3:721–732.
   PubMed Web of Science ®Google Scholar
• MAXWELL PH, RATCLIFFE PJ: Oxygen sensors and angiogenesis. Semin. Cell Dev. Biol. (2002) 13:29–37.
   PubMed Web of Science ®Google Scholar
• HARRIS AL: Hypoxia - a key regulatory factor in tumour growth. Nat. Rev Cancer (2002) 2:38–47.
   PubMed Web of Science ®Google Scholar
• WENGER RH: Cellular adaptation to hypoxia: 02-sensing protein hydroxylases, hypoxia-inducible transcription factors, and 02-regulated gene expression. FASEB (2002) 16:1151–1162.
   PubMed Web of Science ®Google Scholar
• MABJEESH NJ, FRAZIER MC, SIMONS JVV, ZHONG H: Hypoida- directed cancer therapy. Expert Opin. Tiler. Patents (2002) 12:777–788.
   Web of Science ®Google Scholar
• JIANG BH, RUE E, WANG GL, ROE R, SEMENZA GL: Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor-1. J. Biol. Chem. (1996) 271:17771–17778.
   PubMed Web of Science ®Google Scholar
• JIANG BH, ZHENG JZ, LEUNG SW, ROE R, SEMENZA GL: Transactivation and inhibitory domains of hypoxia-inducible factor-1a. Modulation of transcriptional activity by oxygen tension. Biol . Chem. (1997) 272:19253–19260.
   PubMed Web of Science ®Google Scholar
• ARANY Z, HUANG LE, ECKNER R et al.: An essential role for p300/CBP in the cellular response to hypoxia. Proc. Natl. Acad. Sci. USA (1996) 93:12969–12973.
   PubMed Web of Science ®Google Scholar
• KALLIO PJ, OKAMOTO K, O'BRIEN S et al.: Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1a. EMBO (1998) 17:6573–6586.
   Google Scholar
• •Demonstration of a multi-step process involving HIF-1 activation, including the CREB-binding protein (CBP)/p300 as a critical coactivator in the process.
   Google Scholar
• HUANG LE, GU J, SCHAU M, BUNN HF: Regulation of hypoxia-inducible factor la is mediated by an 02-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Nati Acad. Sci. USA (1998) 95:7987–7992.
   PubMed Web of Science ®Google Scholar
• ••Primary identification of an oxygen- dependent degradation (ODD) domain within HIF- la that controls its degradation by the ubiquitin-proteasome pathway.
   Google Scholar
• IVAN M, KONDO K, YANG H et al: HIF-a targeted for VHL-mediated destruction by proline hydroxylation: implications for 02 sensing. Science (2001) 292:464–468.
   PubMed Web of Science ®Google Scholar
• ••Demonstration of proline hydroxylation as a key step in HIE-a degradation.
   Google Scholar
• JAAKKOLA P, MOLE DR, TIAN YM Targeting of HIF-a to the von Hippel-Lindau ubiquitylation complex by 02-regulated prolyl hydroxylation. Science (2001) 292:468–472.
   PubMed Web of Science ®Google Scholar
• ••Demonstration of proline hydroxylation asa key step in HIE-a degradation.
   Google Scholar
• MASSON N, WILLAM C, MAXWELL PH, PUGH CW, RATCLIFFE PJ: Independent function of two destruction domains in hypoxia-inducible factor-a chains activated by prolyl hydroxylation. EMBO (2001) 20:5197–5206.
   PubMed Web of Science ®Google Scholar
• YU F, WHITE SB, ZHAO Q, LEE FS: HIF-1a binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. USA (2001) 98:9630–9635.
   PubMed Web of Science ®Google Scholar
• TIAN H, MCKNIGHT SL, RUSSELL DW: Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. (1997) 11:72–82.
   PubMed Web of Science ®Google Scholar
• EMA M, TAYA S, YOKOTANI N, SOGAWA K, MATSUDA Y, FUJII-KURIYAMA Y: A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor-1a regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl. Acad. Sci. USA (1997) 94:4273–4278.
   PubMed Web of Science ®Google Scholar
• FLAMME I, FROHLICH T, VON REUTERN M, KAPPEL A, DAMERT A, RISAU W: HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1a and developmentally expressed in blood vessels. Mech . Dev. (1997) 63:51–60.
   PubMed Web of Science ®Google Scholar
• GU YZ, MORAN SM, HOGENESCH JB, WARTMAN L, BRADFIELD CA: Molecular characterization and chromosomal localization of a third a-class hypoxia inducible factor subunit, HIF-3a. Gene Expr. (1998) 7:205–213.
   PubMed Web of Science ®Google Scholar
• KIETZMANN T, CORNESSE Y, BRECHTEL K, MODARESSI S, JUNGERMANN K: Perivenous expression of the mRNA of the three hypoxia-inducible factor a-subunits, HIF- la, HIF-2a and HIF-3a, in rat liver. Biochem. J. (2001) 354:531–537.
   PubMed Web of Science ®Google Scholar
• ZHONG H, MABJEESH N, WILLARD M, SIMONS J: Nuclear expression of hypoxia-inducible factor-la protein is heterogeneous in human malignant cells under normoxic conditions. Cancer Lett. (2002) 181:233–238.
   PubMed Web of Science ®Google Scholar
• MAXWELL PH, WIESENER MS, CHANG GW et al: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 399:271–275.
   PubMed Web of Science ®Google Scholar
• •Identification of the pVHL/HIF-1 interaction in the process of HIF-a degradation.
   Google Scholar
• OHH M, PARK CW, IVAN M et al.: Ubiquitination of hypoxia-inducible factor requires direct binding to the 13-domain of the von Hippel-Lindau protein. Nat. Cell Biol. (2000) 2:423–427.
   PubMed Web of Science ®Google Scholar
• COCKMAN ME, MASSON N, MOLE DR et al.: Hypoxia inducible factor-a binding and ubiquitylation by the von Hippel-Lindau tumour suppressor protein. J. Biol. Chem. (2000) 275:25733–25741.
   PubMed Web of Science ®Google Scholar
• KAMURA T, SATO S, IWAI K, CZYZYK -KRZESKA M, CONAWAY RC, CONAWAY JW: Activation of HIF1 a ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumour suppressor complex. Proc. Nati Acad. ScL USA (2000) 97:10430–10435.
   PubMed Web of Science ®Google Scholar
• TANIMOTO K, MAKINO Y, PEREIRA T, POELLINGER L: Mechanism of regulation of the hypoxia-inducible factor-1a by the von Hippel-Lindau tumour suppressor protein. EMBO (2000) 19:4298–4309.
   PubMed Web of Science ®Google Scholar
• •A study showing that pVHL is a limiting factor for HIF-la degradation.
   Google Scholar
• BRUICK RK, MCKNIGHT SL: A conserved family of proly1-4-hydroxylases that modify HIE Science (2001) 294:1337–1340.
   Google Scholar
• ••Identification of mammalian PHDs thathydroxylate HIF-a.
   Google Scholar
• EPSTEIN AC, GLEADLE JM, MCNEILL LA et al: C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell (2001) 107:43–54.
   Google Scholar
• ••Identification of mammalian PHDs thathydroxylate HIF-a.
   Google Scholar
• IWAI K, YAMANAKA K, KAMURA T et al.: Identification of the von Hippel-lindau suppressor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc. Nati Acad. Sci. USA (1999) 96:12436–12441.
   PubMed Web of Science ®Google Scholar
• LISZTWAN J, IMBERT G, WIRBELAUER C, GSTAIGER M, KREK W: The von Hippel-Lindau tumour suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. (1999) 13:1822–1833.
   PubMed Web of Science ®Google Scholar
• JEONG JVV, BAE MK, AHN MY et aL: Regulation and destabilization of HIF-la by ARD1-mediated acetylation. Cell (2002) 111:709–720.
   PubMed Web of Science ®Google Scholar
• MAHON PC, HIROTA K, SEMENZA GL: FIH-1: a novel protein that interacts with HIF-la and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. (2001) 15:2675–2686.
   PubMed Web of Science ®Google Scholar
• HEWITSON KS, MCNEILL LA, RIORDAN MV et al.: Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J.Biol. Chem. (2002) 277:26351–26355.
   PubMed Web of Science ®Google Scholar
• MCNEILL LA, HEWITSON KS, CLARIDGE TD, SEIBEL JF, HORSFALL LE, SCHOFIELD CJ: Hypwda-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the 13-carbon of asparagine-803. Biochem. 1 (2002) 367:571-575.
   Google Scholar
• LANDO D, PEET DJ, GORMAN JJ, WHELAN DA, WHITELAW ML, BRUICK RK: FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. (2002) 16:1466–1471.
   PubMed Web of Science ®Google Scholar
• LANDO D, PEET DJ, WHELAN DA, GORMAN JJ, WHITELAW ML: Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science (2002) 295:858–861.
   PubMed Web of Science ®Google Scholar
• ••The authors show evidence that thehydroxylation of a conserved asparagine in the C-TAD of HIF-a blocks the interaction of HIF-a with the p300 transcription coactivator.
   Google Scholar
• DANN CE, 3RD, BRUICK RK, DEISENHOFER J: Structure of factor-inhibiting hypoxia-inducible factor-1: An asparaginyl hydroxylase involved in the hypoxic response pathway. Proc . Nati Acad. Sci. USA (2002) 99:15351–15356.
   PubMed Web of Science ®Google Scholar
• MOELLING K, SCHAD K, BOSSE M, ZIMMERMANN S, SCHWENEKER M: Regulation of Raf-Akt Cross-talk. j. Biol. Chem. (2002) 277:31099–31106.
   PubMedGoogle Scholar
• JUN T, GJOERUP 0, ROBERTS TM: Tangled webs: evidence of cross-talk between c-Raf-1 and Akt. Sci. STKE(1999) PEI.
   Google Scholar
• BUNN HF, POYTON RO: Oxygen sensing and molecular adaptation to hypoxia. PhysioL Rev. (1996) 76:839–885.
   PubMed Web of Science ®Google Scholar
• GORLACH A, HOLTERMANN G, JELKMANN W et al.: Photometric characteristics of haem proteins in erythropoietin-producing hepatoma cells (HepG2). Biochem. J. (1993) 290(3):771–776.
   PubMed Web of Science ®Google Scholar
• CHANDEL NS, MCCLINTOCK DS, FELICIANO CE et al: Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1a during hypoxia: a mechanism of 02 sensing. J. Biol. Chem. (2000) 275:25130–25138.
   PubMed Web of Science ®Google Scholar
• HUANG LE, ARANY Z, LIVINGSTON DM, BUNN HF: Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its a-subunit. J. Biol. Chem. (1996) 271:32253–32259.
   PubMed Web of Science ®Google Scholar
• LIU Q, BERCHNER -PFANNSCHMIDT U, MOLLER U et al.: A Fenton reaction at the endoplasmic reticulum is involved in the redox control of hypoxia-inducible gene expression. Proc. Nati Acad. ScL USA (2004) 101:4302–4307.
   PubMed Web of Science ®Google Scholar
• ZHONG H, AGANI F, BACCALA AA et al.: Increased expression of hypoxia inducible factor-1a in rat and human prostate cancer. Cancer Res. (1998) 58:5280–5284.
   PubMed Web of Science ®Google Scholar
• •Primary discovery that the expression of HIF-la protein in normoxic human cancer cells.
   Google Scholar
• ZHONG H, CHILES K, FELDSER D et al.: Modulation of hypoxia-inducible factor la expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/Akt/FRAP pathway in human prostate cancer cells: implications for tumour angiogenesis and therapeutics. Cancer Res. (2000) 60:1541–1545.
   PubMed Web of Science ®Google Scholar
• •Identification of the RTK /PI3K/Akt/FRAP as an oxygen-independent pathway leading to HIF-la expression.
   Google Scholar
• MABJEESH NJ, WILLARD MT, FREDERICKSON CE, ZHONG H, SIMONS JW: Androgens stimulate hypoxia-inducible factor-1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3-kinase/protein kinase B in prostate cancer cells. Clin. Cancer Res. (2003) 9:2416–2425.
   PubMed Web of Science ®Google Scholar
• AKENO N, ROBINS J, ZHANG M, CZYZYK-KRZESKA ME CLEMENS TL: Induction of vascular endothelial growth factor by IGF-I in osteoblast-like cells is mediated by the PI3K signaling pathway through the hypoxia-inducible factor-2a. Endocrinology (2002) 143:420–425.
   PubMed Web of Science ®Google Scholar
• FUKUDA R, HIROTA K, FAN F, JUNG YD, ELLIS LM, SEMENZA GL: Insulin-like growth factor-1 induces hypoxia-inducible factor- 1 -mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells." Biol. Chem. (2002) 277:38205–38211.
   PubMed Web of Science ®Google Scholar
• STIEHL DP, JELKMANN W, WENGER RH, HELLWIG-BU-RGEL T: Normoxic induction of the hypoxia-inducible factor-1a by insulin and interleukin-113 involves the phosphatidylinositol 3-kinase pathway. FEBS Lett. (2002) 512:157–162.
   PubMed Web of Science ®Google Scholar
• LAUGHNER E, TAGHAVI P, CHILES K, MAHON PC, SEMENZA GL: HERZ (neu) signaling increases the rate of hypoxia-inducible factor-1a (HIF-1a) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Md. Cell Biol. (2001) 21:3995–4004.
   Web of Science ®Google Scholar
• •Evidence is provided that the activity of PI3K/Akt/FRAP signalling cascade increases HIF-la synthesis, directed by the 5'-untranslated region of HIF-la mRNA.
   Google Scholar
• SANG N, STIEHL DP, BOHENSKY J, LESHCHINSKY I, SRINIVAS V, CARO J: MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. Biol Chem. (2003) 278:14013–14019.
   Web of Science ®Google Scholar
• SANG N, FANG J, SRINIVAS V, LESHCHINSKY I, CARO J: Carboxyl-terminal transactivation activity of hypoxia-inducible factor-1a is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Ma Cell Biol. (2002) 22:2984–2992.
   Web of Science ®Google Scholar
• KIETZMANN T, SAMOYLENKO A, ROTH U, JUNGERMANN K: Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes. Blood (2003) 101:907–914.
   PubMed Web of Science ®Google Scholar
• SCANDURRO AB, WELD ON CW, FIGUEROA YG, ALAMJ, BECKMAN BS: Gene microarray analysis reveals a novel hypoxia signal transduction pathway in human hepatocellular carcinoma cells. Int. Omni (2001) 19:129–135.
   Google Scholar
• MOTTET D, DUMONT V, DECCACHE Yet al.: Regulation of hypoxia-inducible factor-1a protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 313 pathway in HepG2 cells. J. Biol. Chem. (2003) 278:31277–31285.
   Google Scholar
• ZHONG H, DE MARZO AM, LAUGHNER E et al.: Overexpression of hypoxia-inducible factor-1a in common human cancers and their metastases. Cancer Res. (1999) 59:5830–5835.
   PubMed Web of Science ®Google Scholar
• ZAGZAGD, ZHONG H, SCALZITTI JM, LAUGHNER E, SIMONS JW, SEMENZA GL: Expression of hypoxia-inducible factor-1a in brain tumours: association with angiogenesis, invasion, and progression. Cancer (2000) 88:2606–2618.
   PubMed Web of Science ®Google Scholar
• KRIEG M, HAAS R, BRAUCH H, ACKERT, FLAMME I, PLATE KH: Up-regulation of hypoxia-inducible factors HIF-la and HIF-2a under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumour suppressor gene loss of function. Oncogene (2000) 19:5435–5443.
   PubMed Web of Science ®Google Scholar
• WIESENER MS, MUNCHENHAGEN PM, BERGER I et al: Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-lain clear cell renal carcinomas. Cancer Res (2001) 61:5215–5222.
   PubMed Web of Science ®Google Scholar
• MANDRIOTA SJ, TURNER KJ, DAVIES DR et al.: HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumour suppressor function in the nephron. Cancer Cell (2002) 1:459–468.
   PubMed Web of Science ®Google Scholar
• HUGHSON MD, HE Z, LIU S, COLEMAN J, SHINGLETON WB: Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma: relationship to mutations of the von Hippel-Lindau tumour suppressor gene. Cancer Genet. Cytogenet. (2003) 143:145–153.
   PubMed Web of Science ®Google Scholar
• WALKER C, GOLDSWORTHY TL, WOLF DC, EVERITT J: Predisposition to renal cell carcinoma due to alteration of a cancer susceptibility gene. Science (1992) 255:1693–1695.
   PubMed Web of Science ®Google Scholar
• YEUNG RS, XIAO GH, JIN F, LEE WC, TESTA JR, KNUDSON AG: Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSO gene. Proc. Natl. Acad. Sci. USA (1994) 91:11413–11416.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI T, HIRAYAMA Y, KOBAYASHI E, KUBO Y, HINO 0: A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat. Genet. (1995) 9:70–74.
   PubMed Web of Science ®Google Scholar
• ARBISERJL, BRAT D, HUNTERS et al:Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. " Am. Acad. Dermatol (2002) 46:376–380.
   PubMed Web of Science ®Google Scholar
• LIU MY, POELLINGER L, WALKER CL: Up-regulation of hypoxia-inducible factor 2a in renal cell carcinoma associated with loss of Tsc-2 tumour suppressor gene. Cancer Res. (2003) 63:2675–2680.
   PubMed Web of Science ®Google Scholar
• BRUGAROLAS JB, VAZQUEZ F, REDDY A, SELLERS WR, KAELIN WG JR.: TSC2 regulates VEGF through mTOR-dependent and -independent pathways . Cancer Cell (2003) 4:147–158.
   Google Scholar
• INOKI K, ZHU T, GUAN KL: TSC 2 mediates cellular energy response to control cell growth and survival. Cell (2003) 115:577–590.
   PubMed Web of Science ®Google Scholar
• ZUNDEL W, SCHINDLER C, HAAS-KOGAN D et al: Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. (2000) 14:391–396.
   PubMed Web of Science ®Google Scholar
• •Forced PTEN overexpression in human glioma cell lines inhibits hypoxia-induced HIE- la expression.
   Google Scholar
• JIANG BH, JIANG G, ZHENG JZ, LU Z, HUNTER T, VOGT PK: Phosphatidylinosito13-kinase signaling controls levels of hypoxia- inducible factor-1. Cell Growth Differ. (2001) 12:363–369.
   PubMedGoogle Scholar
• GOMEZ-MANZANO C, FUEYO J, JIANG H et al.: Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis. Ann. Neurol (2003) 53:109–117.
   PubMed Web of Science ®Google Scholar
• HOPKIN K: A surprising function for the PTEN tumour suppressor. Science (1998) 282:1027,1029–1030.
   Google Scholar
• SEMENZA GL: HIF-1 and human disease: one highly involved factor. Genes Dev. (2000) 14:1983–1991.
   PubMed Web of Science ®Google Scholar
• GIACCIA A, SIIM BG, JOHNSON RS: HIF-1 as a target for drug development. Nat. Rev Drug Discov. (2003) 2:803–811.
   PubMed Web of Science ®Google Scholar
• SANDAU KB, ZHOU J, KIETZMANN T, BRUNE B: Regulation of the hypoxia-inducible factor-1a by the inflammatory mediators nitric oxide and tumour necrosis factor-a in contrast to desferroxamine and phenylarsine oxide. Biol Chem. (2001) 276:39805–39811.
   Web of Science ®Google Scholar
• TREINS C, GIORGETTI-PERALDI S, MURDACA J, SEMENZA GL, VAN OBBERGHEN E: Insulin stimulates hypoxia-inducible factor-1 through a phosphatidylinositol 3-kinaseharget of rapamycin-dependent signaling pathway. J. Biol. Chem. (2002) 277:27975–27981.
   PubMed Web of Science ®Google Scholar
• ZHOU J, FANDREY J, SCHUMANN J, TIEGS G, BRUNE B: NO and TNF-a released from activated macrophages stabilize HIF-la in resting tubular LLC-PK1 cells. Am. J. Physic] Cell Physiol (2003) 284:C439–446.
   Web of Science ®Google Scholar
• JUNG YJ, ISAACS JS, LEE S, TREPEL J, NECKERS L: IL-1I3-mediated up-regulation of HIF-la via an NFicB/C0X-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB (2003) 17:2115–2117.
   PubMed Web of Science ®Google Scholar
• SANDAU KB, FAUS HG, BRUNE B: Induction of hypoxia-inducible-factor-1 by nitric oxide is mediated via the PI3K pathway. Biochem. Biophys. Res. Commun. (2000) 278:263–267.
   PubMed Web of Science ®Google Scholar
• FUKUDA R, KELLY B, SEMENZA GL: Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor-1. Cancer Res. (2003) 63:2330–2334.
   PubMed Web of Science ®Google Scholar
• GAO N, DING M, ZHENG JZ et al: Vanadate-induced expression of hypoxia-inducible factor-1a and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J. Biol. Chem. (2002) 277:31963–31971.
   PubMed Web of Science ®Google Scholar
• KIM CH, CHO YS, CHUN YS, PARK JW, KIM MS: Early expression of myocardial HIF-la in response to mechanical stresses: regulation by stretch-activated channels and the phosphatidylinositol 3-kinase signaling pathway. Circ. Res. (2002) 90:E25–33.
   PubMed Web of Science ®Google Scholar
• SARAMAKI OR, SAVINAINEN KJ, NUPPONEN NN, BRATT 0, VISAKORPI T: Amplification of hypoxia-inducible factor-1a gene in prostate cancer. Cancer Genet. Cytogenet. (2001) 128:31–34.
   PubMedGoogle Scholar
• HANZE J, EUL BG, SAVAI R et al.: RNA interference for HIF- la inhibits its downstream signalling and affects cellular proliferation. Biochem. Biophys. Res. Commun. (2003) 312:571–577.
   PubMed Web of Science ®Google Scholar
• SOWTER HM, RAVAL R, MOORE J, RATCLIFFE PJ, HARRIS AL: Predominant role of hypoxia-inducible transcription factor (HIF)-la versus HIF-2a in regulation of the transcriptional response to hypoxia. Cancer Res. (2003) 63:6130–6134.
   PubMed Web of Science ®Google Scholar
• SUN X, KANWAR JR, LEUNG E, LEHNERT K, WANG D, KRISSANSEN GW: Gene transfer of antisense hypoxia inducible factor-1a enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther. (2001) 8:638–645.
   PubMed Web of Science ®Google Scholar
• CANIGGIA I, MOSTACHFI H, WINTER J et al.: Hypwda-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFI3(3). Clin. Invest. (2000) 105:577–587.
   Google Scholar
• COMERFORD KM, WALLACE TJ, KARHAUSEN J, LOUIS NA, MONTALTO MC, COLGAN SP: Hypwda -inducible factor-l-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. (2002) 62:3387–3394.
   PubMed Web of Science ®Google Scholar
• SYNNESTVEDT K, FURUTA GT, COMERFORD KM et al: Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest. (2002) 110:993–1002.
   PubMed Web of Science ®Google Scholar
• POULAKI V, MITSIADES CS, MCMULLAN C et al: Regulation of vascular endothelial growth factor expression by insulin-like growth factor-1 in thyroid carcinomas. j Clin. Endocrinol Metab. (2003) 88:5392–5398.
   PubMed Web of Science ®Google Scholar
• RAVI R, MOOKERJEE B, BHUJWALLA ZM et al.: Regulation of tumour angiogenesis by p53-induced degradation of hypoxia-inducible factor- la. Genes Dev. (2000) 14:34–44.
   PubMed Web of Science ®Google Scholar
• LIU LX, LU H, LUO Y et al: Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor-1. Biochem. Biophys. Res. Commun. (2002) 291:908–914.
   PubMed Web of Science ®Google Scholar
• ELSON DA, THURSTON G, HUANG LE et al.: Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1a. Genes Dev (2001) 15:2520–2532.
   PubMed Web of Science ®Google Scholar
• PEREIRA T, ZHENG X, RUAS JL, TANIMOTO K, POELLINGER L: Identification of residues critical for regulation of protein stability and the transactivation function of the hypoxia-inducible factor-1a by the von Hippel-Lindau tumour suppressor gene product. J. Biol. Chem. (2003) 278:6816–6823.
   PubMed Web of Science ®Google Scholar
• VINCENT KA, SHYU KG, LUO Y et al: Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-laNP 16 hybrid transcription factor. Circulation (2000) 102:2255–2261.
   PubMed Web of Science ®Google Scholar
• •The authors show that the HIF- a/VP16, a constitutively active hybrid protein, is a good tool for therapeutic angiogenesis in which neovascularisation may be achieved. In a rabbit model of hindlinrib ischaemia, administration of HIF- laNP16 significantly improves calf blood pressure ratio, angiographic score, resting and maximal regional blood flow and capillary density.
   Google Scholar
• SHYU KG, WANG MT, WANG BW et al.: Intramyocardial injection of naked DNA encoding HIF-laNP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc. Res. (2002) 54:576–583.
   PubMed Web of Science ®Google Scholar
• SEMENZA GL: Regulation of erythropoietin production. New insights into molecular mechanisms of oxygen homeostasis. Hematol. Oncol Clin. North Am. (1994) 8:863–884.
   PubMed Web of Science ®Google Scholar
• WANG GL, SEMENZA GL: Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor-1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood (1993) 82:3610–3615.
   PubMed Web of Science ®Google Scholar
• BAADER E, TSCHANK G, BARINGHAUS KH, BURGHARD H, GUNZLER V: Inhibition of prolyl 4-hydroxylase by oxalyl amino acid derivatives M vitro, in isolated microsomes and in embryonic chicken tissues. Biochem. J. (1994) 300(2):525–530.
   PubMed Web of Science ®Google Scholar
• GUNZLER V, HANAUSKE-ABEL HM, MYLLYLA R, KASKA DD, HANAUSKE A, KIVIRIKKO KI: Syncatalytic inactivation of prolyl 4-hydroxylase by anthracyclines. Biochem . J. (1988) 251:365–372.
   PubMed Web of Science ®Google Scholar
• MAJAMAA K, HANAUSKE-ABEL HM, GUNZLER V, KIVIRIKKO KI: The 2-oxoglutarate binding site of prolyl 4-hydroxylase. Identification of distinct subsites and evidence for 2-oxoglutarate decarboxylation in a ligand reaction at the enzyme-bound ferrous ion. Eur . Biochem. (1984) 138:239–245.
   Google Scholar
• TSCHANK G, RAGHUNATH M, GUNZLER V, HANAUSKE-ABEL HM: Pyridinedicarboxylates, the first mechanism-derived inhibitors for prolyl 4-hydroxylase, selectively suppress cellular hydroxyprolyl biosynthesis. Decrease in interstitial collagen and Clq secretion in cell culture. Biochem. J. (1987) 248:625–633.
   Google Scholar
• FRANKLIN TJ, MORRIS WP, EDWARDS PN, LARGE MS, STEPHENSON R: Inhibition of prolyl 4-hydroxylase M vitro and in vivo by members of a novel series of phenanthrolinones. Biochem. J. (2001) 353:333–338.
   PubMed Web of Science ®Google Scholar
• IVAN M, HABERBERGER T, GERVASI DC et al.: Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc. Natl. Acad. Sci. USA (2002) 99:13459–13464.
   PubMed Web of Science ®Google Scholar
• HON WC, WILSON MI, HARLOS K et al.: Structural basis for the recognition of hydroxyproline in HIF-la by pVHL. Nature (2002) 417:975–978.
   PubMed Web of Science ®Google Scholar
• LI J, POST M, VOLK R et al: PR39, a peptide regulator of angiogenesis. Nat. Med. (2000) 6:49–55.
   PubMed Web of Science ®Google Scholar
• •A macrophage-derived peptide, PR39, inhibits the 26S proteasome dependent degradation of HIF-la, resulting in accelerated formation of vascular structures in vitro and increased myocardial vasculature in mice.
   Google Scholar
• GACZYNSKA M, OSMULSKI PA, GAO Y, POST MJ, SIMONS M: Proline-and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity. Biochemistry (2003) 42:8663–8670.
   PubMed Web of Science ®Google Scholar
• SALCEDA S, CARO J: Hypoxia-inducible factor-la (HIF-1a) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. Biol. Chem. (1997) 272:22642–22647.
   Google Scholar
• MABJEESH NJ, POST DE, WILLARD MT et al.: Geldanamycin induces degradation of HIF-1 a protein via the proteosome pathway in prostate cancer cells. Cancer Res. (2002).
   Google Scholar
• EGUCHI H, IKUTA T, TACHIBANA T, YONEDA Y, KAWAJIRI K: A nuclear localization signal of human aryl hydrocarbon receptor nuclear translocator/hypoxia-inducible factor-1I3 is a novel bipartite type recognized by the two components of nuclear pore-targeting complex. Biol. Chem. (1997) 272:17640–17647.
   Web of Science ®Google Scholar
• LUO JC, SHIBUYA M: A variant of nuclear localization signal of bipartite-type is required for the nuclear translocation of hypoxia inducible factors (la, 2a and 3a). Oncogene (2001) 20:1435–1444.
   PubMed Web of Science ®Google Scholar
• MAKINO Y, CAO R, SVENSSON K et al.: Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature (2001) 414:550–554.
   PubMed Web of Science ®Google Scholar
• MAKINO Y, KANOPKA A, WILSON WJ, TANAKA H, POELLINGER L: Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3a locus. J. Biol. Chem. (2002) 277:32405–32408.
   PubMed Web of Science ®Google Scholar
• MAYNARD MA, QI H, CHUNG J et al.: Multiple splice variants of the human HIF-3a locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex.i. Biol. Chem. (2003) 278:11032–11040.
   Google Scholar
• RUAS JL, POELLINGER L, PEREIRA T: Functional analysis of hypoxia-inducible factor- 1 a-mediated transactivation. Identification of amino acid residues critical for transcriptional activation and/or interaction with CREB-binding protein. J. Biol. Chem. (2002) 277:38723–38730.
   Google Scholar
• YANG DI, CHEN SD, YANG YT, JU TC, XU JM, HSU CY: Carbamoylating chemoresistance induced by cobalt pretreatment in C6 glioma cells: putative roles of hypoxia-inducible factor-1. Br. J. Pharmacol. (2004) 141:988–996.
   PubMed Web of Science ®Google Scholar
• ROSE F, GRIMMINGER F, APPEL J et al.: Hypoxic pulmonary artery fibroblasts trigger proliferation of vascular smooth muscle cells: role of hypoxia-inducible transcription factors. FASEB J. (2002) 16:1660–1661.
   PubMed Web of Science ®Google Scholar
• YANG ZZ, ZOU AP: Transcriptional regulation of heme oxygenases by HIF la -in renal medullary interstitial cells. Am. J. Physiol. Renal Physiol. (2001) 281:F900–F908.
   Web of Science ®Google Scholar
• OIKAWA M, ABE M, KUROSAWA H, HIDA W, SHIRATO K, SATO Y: Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1. Biochem. Biophys. Res. Commun. (2001) 289:39–43.
   PubMed Web of Science ®Google Scholar
• DATTA K, LI J, BHATTACHARYA R, GASPARIAN L, WANG E, MUKHOPADHYAY D: Protein kinase C-transactivates hypoxia-inducible factor-a by promoting its association with p300 in renal cancer. Cancer Res. (2004) 64:456–462.
   PubMed Web of Science ®Google Scholar
• TANIMOTO K, YOSHIGA K, EGUCHI H et al.: Hypoxia-inducible factor-la polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis (2003) 24:1779–1783.
   PubMed Web of Science ®Google Scholar
• YOKOZAWA T, LIU ZW, DONG E: A study of ginsenoside-Rd in a renal ischemia-reperfusion model. Nephron (1998) 78:201–206.
   PubMed Web of Science ®Google Scholar
• LIM JH, WEN TC, MATSUDA S et al: Protection of ischemic hippocampal neurons by ginsenoside Rb1, a main ingredient of ginseng root. Neurosci. Res. (1997) 28:191–200.
   PubMed Web of Science ®Google Scholar
• WEN TC, YOSHIMURA H, MATSUDA S, LIM JH, SAKANAKA M: Ginseng root prevents learning disability and neuronal loss in gerbils with 5-minute forebrain ischemia. Acta Neuropathol. (Berl) (1996) 91:15–22.
   PubMed Web of Science ®Google Scholar
• DOU DQ, ZHANG YVV, ZHANG L, CHEN YJ, YAO XS: The inhibitory effects of ginsenosides on protein tyrosine kinase activated by hypcoda/reoxygenation in cultured human umbilical vein endothelial cells. Planta Med. (2001) 67:19–23.
   PubMed Web of Science ®Google Scholar
• MABJEESH NJ, WILLARD MT, HARRIS WB et al.: Dibenzoylmethane, a natural dietary compound, induces HIF-la and increases expression of VEGF. Biochem. Biophys. Res. Commun. (2003) 303:279–286.
   PubMed Web of Science ®Google Scholar
• RALEIGH JA, CALKINS-ADAMS DP, RINKER LH et al.: Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res. (1998) 58:3765–3768.
   PubMed Web of Science ®Google Scholar
• FOGLESONG PD, RECKORD C, SWINK S: Doxorubicin inhibits human DNA topoisomerase I. Cancer Chemothec Pharmacol. (1992) 30:123–125.
   PubMed Web of Science ®Google Scholar
• RAPISARDA A, URANCHIMEG B, SCUDIERO DA et al.: Identification of small molecule inhibitors of hypoxia-inducible factor-1 transcriptional activation pathway. Cancer Res. (2002) 62:4316–4324.
   PubMed Web of Science ®Google Scholar
• MABJEESH NJ, ESCUIN D, LAVALLEE TM et al: 2ME2 inhibits tumour growth and angiogenesis by disrupting microtubules and dysregulating HIE Cancer Cell (2003) 3:363–375.
   Google Scholar
• WELSH SJ, WILLIAMS RR, BIRMINGHAM A, NEWMAN DJ, KIRKPATRICK DL, POWIS G: The thioredoxin redox inhibitors 1-methylpropyl 2-imidazoly1 disulfide and pleurotin inhibit hypoxia-induced factor-1a and vascular endothelial growth factor formation. Ma Cancer Thec (2003) 2:235–243.
   PubMed Web of Science ®Google Scholar
• WELSH SJ, BELLAMY WT, BRIEHL MM, POWIS G: The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor-1a protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumour angiogenesis. Cancer Res. (2002) 62:5089–5095.
   PubMed Web of Science ®Google Scholar
• NAGASAWA H, MIKAMO N, NAKAJIMA Y, MATSUMOTO H, UTO Y, HORI H: Antiangiogenic hypoxic cytotoxin TX-402 inhibits hypoxia-inducible factor-1 signaling pathway. Anti-Cancer Res. (2003) 23:4427–4434.
   PubMed Web of Science ®Google Scholar
• MIE LEE Y, KIM SH, KIM HS et al.: Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1 a activity. Biochein. Biophys. Res. Commun. (2003) 300:241–246.
   PubMed Web of Science ®Google Scholar
• SCOTT PA, GLEADLE JM, BICKNELL R, HARRIS AL: Role of the hypoxia sensing system, acidity and reproductive hormones in the variability of vascular endothelial growth factor induction in human breast carcinoma cell lines. bt.j Cancer(1998) 75:706–712.
   Web of Science ®Google Scholar
• BABA M, HIRAI S, YAMADA-OKABE H et al.: Loss of von Hippel-Lindau protein causes cell density dependent deregulation of Cyclin D1 expression through hypoxia-inducible factor. Oncogene (2003) 22:2728–2738.
   PubMed Web of Science ®Google Scholar
• MAZURE NM, CHEN EY, LADEROUTE KR, GIACCIA AJ: Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood(i997) 90:3322-3331.
   Google Scholar
• CHEN EY, MAZURE NM, COOPER JA, GIACCIA AJ: Hypoxia activates a platelet-derived growth factor receptor/ phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res (2001) 61:2429–2433.
   PubMed Web of Science ®Google Scholar
• CHAN DA, SUTPHIN PD, DENKO NC, GIACCIA AJ: Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1a. Biol. Chem. (2002) 277:40112–40117.
   Web of Science ®Google Scholar
• METZEN E, ZHOU J, JELKMANN W, FANDREY J, BRUNE B: Nitric oxide impairs normoxic degradation of HIF-la by inhibition of prolyl hydroxylases. Biol. Cell(2003) 14:3470–3481.
   Web of Science ®Google Scholar
• KASUNO K, TAKABUCHI S, FUKUDA K et al.: Nitric oxide induces hypoxia-inducible factor-1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. 'Bib/. Chem. (2004) 279:2550–2558.
   PubMed Web of Science ®Google Scholar
• AEBERSOLD DM, BURRIP, BEER KT et al.: Expression of hypoxia-inducible factor-1a: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. (2001) 61:2911–2916.
   PubMed Web of Science ®Google Scholar
• BEASLEY NJ, LEEK R, ALAM M et al.: Hypoxia-inducible factors HIF-la and HIF-2a in head and neck cancer: relationship to tumour biology and treatment outcome in surgically resected patients. Cancer Res. (2002) 62:2493–2497.
   PubMed Web of Science ®Google Scholar
• SHARP FR, BERGERON M, BERNAUDIN M: Hypoxia-inducible factor in brain. Adv. Exp. Med. Biol. (2001) 502:273–291.
   PubMed Web of Science ®Google Scholar
• CAI Z, MANALO DJ, WEI G et al: Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation (2003) 108:79–85.
   PubMed Web of Science ®Google Scholar
• LINKE S, STOJKOSKI C, KEWLEY RJ, BOOKER GW, WHITELAW ML, PEET DJ: Substrate requirements of the oxygen-sensing asparaginyl hydroxylase factor inhibiting HIE Biol. Chem. (2004) 279:14391–14397.
   Web of Science ®Google Scholar
• BERRA E, BENIZRI E, GINOUVES A, VOLMAT V, ROUX D, POUYSSEGURJ: HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-la in normoxia. EMBO (2003) 22:4082–4090.
   PubMed Web of Science ®Google Scholar
• D'ANGELO G, DUPLAN E, BOYER N, VIGNE P, FRELIN C: Hypoxia up-regulates prolyl hydroxylase activity: a feedback mechanism that limits HIF-1 responses during reoxygenation. Biol. Chem. (2003) 278:38183–38187.
   Web of Science ®Google Scholar
• ISAACS JS, JUNG YJ, NECKERS L: ARNT promotes oxygen-independent stabilization of hypoxia inducible factor-1 a by modulating an Hsp90-dependent regulatory pathway. Biol . Chem. (2004).
   Google Scholar
• ZHOU J, SCHMID T, FRANK R, BRUNE B: PI3K/Akt is required for heat shock proteins to protect HIF-la from pVHL-independent degradation.j Biol. Chem. (2004).
   Google Scholar
• SHIMODA LA, SEMENZA GL: Functional analysis of the role of hypoxia-inducible factor 1 in the pathogenesis of hypoxic pulmonary hypertension. Methods Enzymol. (2004) 381:121–129.
   PubMed Web of Science ®Google Scholar
• SEMENZA GL: 02-regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF-1. Appi Physiol. (2004) 96:1173–1177.
   PubMed Web of Science ®Google Scholar
• ZHONG H, SEMENZA GL, SIMONS JW, DE MARZO AM: Up-regulation of hypoxia-inducible factor-1a is an early event in prostate carcinogenesis. Cancer Detect. Prey (2004) 28:88–93.
   PubMedGoogle Scholar
• BOS R, ZHONG H, HANRAHAN CF et al.: Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. Nati Cancer Inst. (2001) 93:309–314.
   PubMed Web of Science ®Google Scholar
• JIANG YA, FAN LF, JIANG CQ et al.: Expression and significance of PTEN, hypoxia-inducible factor-1a in colorectal adenoma and adenocarcinoma. World Castroenterol. (2003) 9:491–494.
   PubMed Web of Science ®Google Scholar
• SCHINDL M, OBERHUBER G, PICHLBAUER EG, OBERMAIR A, BIRNER P, KELLEY MR: DNA repair-redox enzyme apurinic endonuclease in cervical cancer: evaluation of redox control of HIF-la and prognostic significance. Int. J. Onto]. (2001) 19:799–802.
   PubMed Web of Science ®Google Scholar
• ELSON DA, RYAN HE, SNOW JW, JOHNSON R, ARBEIT JM: Coordinate up-regulation of hypoxia inducible factor (HIF)-la and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing. Cancer Res. (2000) 60:6189–6195.
   PubMed Web of Science ®Google Scholar
• KOUKOURAKIS MI, GIATROMANOLAKI A, SKARLATOS J et al.: Hypoxia inducible factor (HIF-la and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res. (2001) 61:1830–1832.
   PubMed Web of Science ®Google Scholar